Pharma BD Deal Intelligence
FTC required Grifols to divest the Talecris Melville NY fractionation facility, the Koate hemophilia product, and two plasma collection centers to Kedrion…
Closing makes Grifols 'the third company worldwide in the hemoderivative sector,' operating ~150 plasmapheresis centers in the US with expected revenue mix of…
Coverage of completion of the Grifols-Talecris transaction characterized as a global plasma-products consolidation event.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Grifols agreed to acquire Talecris for ~$3.4B (cash + non-voting shares: $19 cash + 0.641 Grifols share = $26.16/share, 53% premium). Created leading global plasma protein company. Closed June 2011 after FTC divestitures.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Grifols SA / Talecris Biotherapeutics Holdings Corp. (this deal) | 2010 | $3.4B | 67 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2010 deals · Immunology deals